Back to Search
Start Over
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
- Source :
-
Current opinion in immunology [Curr Opin Immunol] 2006 Apr; Vol. 18 (2), pp. 206-13. Date of Electronic Publication: 2006 Feb 07. - Publication Year :
- 2006
-
Abstract
- Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Concurrent recognition of the potential importance of inhibitory immune regulators in limiting antitumor responses, either as a result of chronic antigenic stimulation or the self-nature of many tumor-selective target antigens, has led to the development of cytotoxic T lymphocyte antigen-4-blocking antibodies as therapeutic anticancer agents. Following extensive preclinical modeling, these agents have entered clinical trials, where they are showing encouraging activity in heavily pretreated patients with advanced-stage disease, particularly with melanoma or renal carcinoma. Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years.
- Subjects :
- Animals
Antigen-Antibody Reactions
Antigens, CD
Antigens, Differentiation drug effects
Antigens, Neoplasm drug effects
CTLA-4 Antigen
Humans
Models, Immunological
Neoplasms immunology
Antibodies, Monoclonal immunology
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Antibodies, Neoplasm immunology
Antibodies, Neoplasm pharmacology
Antibodies, Neoplasm therapeutic use
Antigens, Differentiation immunology
Antigens, Neoplasm immunology
Immunotherapy methods
Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0952-7915
- Volume :
- 18
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Current opinion in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 16464564
- Full Text :
- https://doi.org/10.1016/j.coi.2006.01.011